Alogliptin benzoate; metformin hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for alogliptin benzoate; metformin hydrochloride and what is the scope of freedom to operate?
Alogliptin benzoate; metformin hydrochloride
is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Alogliptin benzoate; metformin hydrochloride has ninety patent family members in forty-one countries.
Three suppliers are listed for this compound.
Summary for alogliptin benzoate; metformin hydrochloride
International Patents: | 90 |
US Patents: | 4 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Clinical Trials: | 2 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for alogliptin benzoate; metformin hydrochloride |
DailyMed Link: | alogliptin benzoate; metformin hydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for alogliptin benzoate; metformin hydrochloride
Generic Entry Date for alogliptin benzoate; metformin hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for alogliptin benzoate; metformin hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Celltrion Pharm, Inc. | Phase 4 |
Takeda | Phase 4 |
Seoul National University Hospital | Phase 4 |
See all alogliptin benzoate; metformin hydrochloride clinical trials
Pharmacology for alogliptin benzoate; metformin hydrochloride
Drug Class | Biguanide Dipeptidyl Peptidase 4 Inhibitor |
Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for alogliptin benzoate; metformin hydrochloride
Paragraph IV (Patent) Challenges for ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
KAZANO | Tablets | alogliptin benzoate; metformin hydrochloride | 12.5 mg/500 mg and 12.5 mg/1000 mg | 203414 | 3 | 2017-01-25 |
US Patents and Regulatory Information for alogliptin benzoate; metformin hydrochloride
Expired US Patents for alogliptin benzoate; metformin hydrochloride
International Patents for alogliptin benzoate; metformin hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 20064669 | ⤷ Try a Trial | |
Georgia, Republic of | P20125672 | ) SOLID COMPOSITION CONTAINING ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | ⤷ Try a Trial |
Japan | 2010533643 | ⤷ Try a Trial | |
Malaysia | 159203 | SOLID PREPARATION COMPRISING ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | ⤷ Try a Trial |
Croatia | P20080509 | ⤷ Try a Trial | |
Spain | 2603879 | ⤷ Try a Trial | |
European Patent Office | 2185138 | PREPARATION SOLIDE COMPRENANT DU ALOGLIPTIN ET METFORMIN CHLORHYDRATE (SOLID PREPARATION COMPRISING ALOGLIPTIN AND METFORMIN HYDROCHLORIDE) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for alogliptin benzoate; metformin hydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1084705 | C01084705/05 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 62955 21.11.2013 |
1586571 | 16/2014 | Austria | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/13/844 (MITTEILUNG) 20130923 |
1586571 | 300640 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/844/001-007 20130923 |
1586571 | C 2014 011 | Romania | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN; NATIONAL AUTHORISATION NUMBER: EU/1/13/844/001 - EU/1/13/844/027; DATE OF NATIONAL AUTHORISATION: 20130919; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/844/001 - EU/1/13/844/027; DATE OF FIRST AUTHORISATION IN EEA: 20130919 |
1586571 | 132014902238640 | Italy | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN IN TUTTE LE FORME PROTETTE DAL BREVETTO DI BASE(VIPIDIA); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/13/844/001 A EU/1/13/844/027, 20130923 |
1586571 | 172 5006-2014 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: EU/1/13/844/001 - EU/1/13/844/027 20130919 |
1586571 | 92374 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE. FIRST REGISTRATION: 20130923 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.